All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Triplet combination of HMA, FLT3 inhibitors, and venetoclax in FLT3-mutated newly diagnosed AML
This study suggests that in older/unfit adult patients with newly diagnosed AML the triplet combination of HMA, FLT3 inhibitor, and venetoclax is...
Efficacy and safety of midostaurin in younger and older patients with FLT3-ITD AML
In the recent phase II AMLSG 16-10 trial (NCT01477606), older patients aged 61–70 years old were included in the treatment cohort with midostaurin. Interim study...
"The AML Hub is a trusted, respected, and comprehensive resource where clinicians and researchers interested in AML can confidently learn about the most exciting and novel clinical and biological advances in the field."
Are you a healthcare professional? What is your speciality?
Please select or type your speciality
By sharing this information, you can help ensure we continue to develop content that is of most relevance for our audience.
Thank you for submitting.